Inventor · disambiguated record
Florian Holsboer
Also filed as: HOLSBOER FLORIAN
8 granted patents·15 pending applications·6 citations·filing 2002–2021
76Inventor score
Files withMAX PLANCK GESELLSCHAFT6HMNC Diagnostics GmbH2HMNC VALUE GMBH2HOLSBOERMASCHMEYER NEUROCHEMIE GMBH2WEBER FRANK2
Top patents by PatentIndex Score
23 records- 0182US10190168B2Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptomsMAX PLANCK GESELLSCHAFT·Filed 2014·Granted Jan 29, 2019·4 cites·8 claims
- 0269US10857129B2V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin levelBRAHMS GMBH·Filed 2019·Granted Dec 8, 2020·0 cites·7 claims
- 0366US9243293B2Genes associated with posttraumatic-stress disorder (PTSD)HOLSBOER FLORIAN·Filed 2009·Granted Jan 26, 2016·2 cites·15 claims
- 0459US10837062B2Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptomsMAX PLANCK GESELLSCHAFT·Filed 2018·Granted Nov 17, 2020·0 cites·10 claims
- 0552US2012094855A1Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)MENKE ANDREAS·Filed 2009·Application pending·0 cites
- 0650US2015150846A1V1b receptor antagonist for use in the treatment of patients having an elevated avp level and/or an elevated copeptin levelHOLSBOERMASCHMEYER NEUROCHEMIE GMBH·Filed 2013·Application pending·0 cites
- 0750US2010216653A1Use of polymorphisms in the tmem132d gene in the prediction and treatment of anxiety disordersMAX PLANCK GESELLSCHAFT·Filed 2008·Application pending·0 cites
- 0850US2021130899A1Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 AntagonistsHMNC Diagnostics GmbH·Filed 2021·Application pending·0 cites
- 0950US2021207199A1Genetic Predictors of a Response to Treatment with CRHR1 AntagonistsHMNC Diagnostics GmbH·Filed 2021·Application pending·0 cites
- 1050US2018042898A1V1b receptor antagonist for use in the treatment of patients having an elevated avp level and/or an elevated copeptin levelMAX PLANCK GESELLSCHAFT·Filed 2017·Application pending·0 cites
- 1148US2007298027A1Novel Target for Antiderpressant TherapyMAX PLANCK GESELLSCHAFT·Filed 2004·Application pending·0 cites
- 1247US2014249090A1Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disordersYEN YI-CHUN·Filed 2012·Application pending·0 cites
- 1346US9115398B2Polymorphisms in ABCB1 associated with a lack of clinical response to medicamentsUHR MANFRED·Filed 2008·Granted Aug 25, 2015·0 cites·32 claims
- 1446US8071299B2Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosisWEBER FRANK·Filed 2007·Granted Dec 6, 2011·0 cites·6 claims
- 1544US2016279204A1Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disordersMAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V·Filed 2015·Application pending·0 cites
- 1640US8030033B2Polymorphisms in ABCB1 associated with a lack of clinical response to medicamentsMAX PLANCK GESELLSCHAFT·Filed 2005·Granted Oct 4, 2011·0 cites·16 claims
- 1740US2015278438A1Genetic predictors of response to treatment with crhr1 antagonistsMAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V·Filed 2013·Application pending·0 cites
- 1839US2013252822A1Methods for Predicting an Antibody Response to Interferon Therapy in Multiple Sclerosis PatientsWEBER FRANK·Filed 2011·Application pending·0 cites
- 1939US2006057568A1Method of identifying compounds that alter bag-1 mediated down-regulation of glucocorticoid-receptor transactivationSCHMIDT ULRIKE·Filed 2002·Application pending·0 cites
- 2037US2015094310A1Crhr1 antagonists for use in the treatment of patients having crh overactivityHOLSBOERMASCHMEYER NEUROCHEMIE GMBH·Filed 2013·Application pending·0 cites
- 2137US2018119221A1Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 AntagonistsHMNC VALUE GMBH·Filed 2016·Application pending·0 cites
- 2234US9901582B2Polymorphisms in ABCB1 associated with a lack of clinical response to medicamentsMAX PLANCK GES ZUR FOERDERUNG DER WISENSCHAFTEN E V·Filed 2015·Granted Feb 27, 2018·0 cites·8 claims
- 2331US2018355430A1Genetic Predictors of a Response to Treatment with CRHR1 AntagonistsHMNC VALUE GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Florian Holsboer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →